StockData
Legend Biotech Corp logo

Legend Biotech Corp (LEGN) stock

LEGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 10, 2026Score 3/30
$16.25+0.14 (+0.87%)

Close on Nov 18, 2026Market cap $3.01BP/E –Yield –

Legend Biotech revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Legend Biotech's revenue for the twelve months ending Jun 30, 2026 was $1.27B, up 59.5% year over year. For fiscal 2025 it was $1.03B, up 64.0% from the year before. The highest annual figure on record is $1.03B in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.03B+64.0%
FY2024Dec 31, 2024$627.30M+120.0%
FY2023Dec 31, 2023$285.10M+143.7%
FY2022Dec 31, 2022$117.01M+70.0%
FY2021Dec 31, 2021$68.83M-8.2%
FY2020Dec 31, 2020$75.00M+25.0%
FY2019Dec 31, 2019$59.98M+22.1%
FY2018Dec 31, 2018$49.13M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$387.50M+51.9%
Q1 FY2026Mar 31, 2026$305.10M+56.5%
Q4 FY2025Dec 31, 2025$306.38M+64.2%
Q3 FY2025Sep 30, 2025$272.33M+70.0%
Q2 FY2025Jun 30, 2025$255.10M+36.8%
Q1 FY2025Mar 31, 2025$195.00M+107.5%
Q4 FY2024Dec 31, 2024$186.58M+134.9%
Q3 FY2024Sep 30, 2024$160.21M+66.9%
Q2 FY2024Jun 30, 2024$186.52M+154.4%
Q1 FY2024Mar 31, 2024$93.99M+158.7%
Q4 FY2023Dec 31, 2023$79.42M+187.4%
Q3 FY2023Sep 30, 2023$96.01M+250.9%
Q2 FY2023Jun 30, 2023$73.33M–
Q1 FY2023Mar 31, 2023$36.34M–
Q4 FY2022Dec 31, 2022$27.63M–
Q3 FY2022Sep 30, 2022$27.36M–

More Legend Biotech figures

See a number that looks wrong?